These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30641718)

  • 21. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic cholesterol synthesis and lipoprotein levels impaired by dietary fructose and saturated fatty acids in mice: Insight on PCSK9 and CD36.
    Nergiz-Unal R; Ulug E; Kisioglu B; Tamer F; Bodur M; Yalcimin H; Yuruk AA
    Nutrition; 2020; 79-80():110954. PubMed ID: 32862122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations Between Soluble LDLR and Lipoproteins in a White Cohort and the Effect of PCSK9 Loss-of-Function.
    Mayne J; Ooi TC; Tepliakova L; Seebun D; Walker K; Mohottalage D; Ning Z; Abujrad H; Mbikay M; Wassef H; Chrétien M; Figeys D
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3486-3495. PubMed ID: 29982529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S; Rodríguez-Pérez C; Ramprasath VR; Segura-Carretero A; Jones PJ
    Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
    Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
    Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
    Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
    Ferraz-Amaro I; López-Mejías R; Ubilla B; Genre F; Tejera-Segura B; de Vera-González AM; González-Rivero AF; Olmos JM; Hernández JL; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6):1013-1019. PubMed ID: 27606890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients.
    Burchardt P; Rzeźniczak J; Dudziak J; Dżumak A; Marchlewski T; Ganowicz-Kaatz T; Popiak M; Słomczyński M; Jezierski M; Laskowski W; Łuczak T; Plewa R
    Cardiol J; 2016; 23(6):604-609. PubMed ID: 27665855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36.
    Fan FS
    Tumour Biol; 2023; 45(1):73-80. PubMed ID: 37694331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study.
    Iqbal A; Jorde R; Figenschau Y
    J Intern Med; 2006 Jul; 260(1):53-61. PubMed ID: 16789979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
    Wang S; Cheng ZY; Zhao ZN; Quan XQ; Wei Y; Xia DS; Li JQ; Hu JL
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1135-9. PubMed ID: 27049268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [No Abstract]   [Full Text] [Related]  

  • 37. Associations between metabolic syndrome, serum thyrotropin, and thyroid antibodies status in postmenopausal women, and the role of interleukin-6.
    Siemińska L; Wojciechowska C; Walczak K; Borowski A; Marek B; Nowak M; Kajdaniuk D; Foltyn W; Kos-Kudła B
    Endokrynol Pol; 2015; 66(5):394-403. PubMed ID: 26457493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial?
    Efstathiadou Z; Bitsis S; Milionis HJ; Kukuvitis A; Bairaktari ET; Elisaf MS; Tsatsoulis A
    Eur J Endocrinol; 2001 Dec; 145(6):705-10. PubMed ID: 11720894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases.
    Brown M; Ahmed S
    Toxicol Appl Pharmacol; 2019 May; 370():170-177. PubMed ID: 30914377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.